By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Elan Corp. et al. v. Teva Pharmaceuticals USA Inc.
1:11-cv-00367; filed April 25, 2011 in the District Court of Delaware
• Plaintiffs: Elan Corp. plc; Elan Pharma International Ltd.
• Defendant: Teva Pharmaceuticals USA Inc.
Infringement of U.S. Patent Nos. 6,228,398 ("Multiparticulate Modified Release Composition," issued May 8, 2001) and 6,730,325 (same title, issued May 4, 2004), licensed to Novartis, following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Novartis' Focalin® XR (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the complaint here.
Celgene Corp. et al. v. Teva Pharmaceuticals Usa, Inc.
2:11-cv-02356; filed April 25, 2010 in the District Court of New Jersey
• Plaintiffs: Celgene Corp.; Novartis Pharmaceuticals Corp.; Novartis Pharma AG
• Defendant: Teva Pharmaceuticals USA, Inc.
Infringement of U.S. Patent Nos. 5,908,850 ("Method of Treating Attention Deficit Disorders with d-Threo Methylphenidate," issued June 1, 1999), 6,355,656 ("Phenidate Drug Formulations Having Diminished Abuse Potential," issued March 12, 2002, with a reexamination certificate issued March 27, 2007), 6,528,530 ("Phenidate Drug Formulations Having Diminished Abuse Potential," issued March 4, 2003), 5,837,284 ("Delivery of Multiple Doses of Medications," issued November 17, 1998), 6,635,284 (same title, issued October 21, 2003), and 7,431,944 ("Delivery of Multiple Doses of Medications," issued October 7, 2008) all licensed exclusively to Novartis in certain fields of use, following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Novartis' Focalin XR® (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the complaint here.
Genentech, Inc. et al. v. Sandoz Inc.
1:11-cv-01076; filed April 22, 2011 in the District Court of Colorado
• Plaintiffs: Genentech, Inc.; Roche Palo Alto LLC
• Defendant: Sandoz Inc.
Infringement of U.S. Patent No. 6,083,953 ("2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol Derivative," issued July 4, 2000) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Roche's Valcyte® (valganciclovir hydrochloride, used to treat cytomegalovirus retinitis and cytomegalovirus disease). View the complaint here.
Wyeth LLC v. Nostrum Pharmaceuticals, LLC et al.
3:11-cv-02280; filed April 21, 2011 in the District Court of New Jersey
• Plaintiff: Wyeth LLC
• Defendants: Nostrum Pharmaceuticals, LLC; Nostrum Laboratories, Inc.; Enem Nostrum Remedies PVT., Ltd.
Infringement of U.S. Patent Nos. 6,274,171 ("Extended release formulation of venlafaxine hydrochloride," issued August 14, 2001), 6,403,120 (same title, issued June 11, 2002), and 6,419,958 (same title, issued July 16, 2002) following a Paragraph IV certification as part of Nostrum's filing of an ANDA to manufacture a generic version of Wyeth's EFFEXOR XR® (venlafaxine hydrochloride, extended release, used to treat depression). View the complaint here.
AstraZeneca AB et al. v. Dr. Reddy's Laboratories Inc. et al.
3:11-cv-02317; filed April 21, 2011 in the District Court of New Jersey
• Plaintiffs: AstraZeneca AB; AstraZeneca LP; Pozen Inc.
• Defendants: Dr. Reddy's Laboratories Inc.; Dr. Reddy's Laboratories Ltd.
Infringement of U.S. Patent No. 6,926,907 ("Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs," issued August 9, 2005) following a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of AstraZeneca's Vimovo® (naproxen and esomeprazole magnesium, used to relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with non-steroidal anti-inflammatory drugs (NSAIDs). View the complaint here.
Novartis AG et al. v. Teva Pharmaceuticals USA, Inc. et al.
2:11-cv-02289; filed April 21, 2011 in the District Court of New Jersey
• Plaintiffs: Novartis AG; Novartis Pharmaceuticals Corp.
• Defendants: Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries, Ltd.
Infringement of U.S. Patent Nos. 6,025,391 ("Enteric-Coated Pharmaceutical Compositions of Mycophenolate," issued February 15, 2000), 6,172,107 ("Entric-Coated Pharmaceutical Compositions," issued January 9, 2001), and 6,306,900 (same title, issued October 23, 2001) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Novartis' Myfortic7 (mycophenolate sodium, used for the prophylaxis or prevention of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids). View the complaint here.
Comments